A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs (NCT04908202)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0197 — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (183 Sites)
Showing the first 25 of 183 sites.
- Local Institution - 0197 — Gilbert, Arizona
- Local Institution - 0188 — Jonesboro, Arkansas
- Local Institution - 0168 — Fontana, California
- Local Institution - 0199 — Fullerton, California
- Local Institution - 0038 — Sacramento, California
- Cohen Medical Centers — Thousand Oaks, California
- Local Institution - 0170 — Denver, Colorado
- Local Institution - 0195 — Clearwater, Florida
- Local Institution - 0272 — Margate, Florida
- Local Institution - 0082 — Miami Lakes, Florida
- Local Institution - 0171 — Gainesville, Georgia
- Local Institution - 0087 — Boise, Idaho
- Local Institution - 0080 — Chicago, Illinois
- Local Institution - 0177 — Orland Park, Illinois
- Local Institution - 0178 — Schaumburg, Illinois
- Local Institution - 0083 — Lexington, Kentucky
- Local Institution - 0042 — Hagerstown, Maryland
- Local Institution - 0198 — Detroit, Michigan
- Local Institution - 0201 — Springfield, Missouri
- Local Institution - 0268 — Kalispell, Montana
- Local Institution - 0186 — Voorhees Township, New Jersey
- University Hospitals Cleveland Medical Center-Dermatology — Cleveland, Ohio
- Local Institution - 0028 — Middleburg Heights, Ohio
- Local Institution - 0179 — Perrysburg, Ohio
- Local Institution - 0182 — Oklahoma City, Oklahoma
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriatic Arthritis
- Psoriatic Arthritis D2P Screening — Philadelphia, Pennsylvania
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis — Dothan, Alabama
- Apremilast Pregnancy Exposure Registry — La Jolla, California
- Psorcast Mobile Study — Seattle, Washington
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy — Anniston, Alabama
Explore by condition: All Psoriatic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.